Colorectal cancer metastatic
Information
- Disease name
- Colorectal cancer metastatic
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
| NCT04867525 | Active, not recruiting | Registry Platform Colorectal Cancer | May 1, 2021 | April 2025 | |
| NCT04940546 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | June 16, 2021 | October 30, 2024 |
| NCT01910610 | Active, not recruiting | Phase 3 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | October 30, 2013 | December 2024 |
| NCT04157322 | Active, not recruiting | Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis | August 26, 2019 | October 31, 2025 | |
| NCT03364621 | Active, not recruiting | Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy | August 29, 2017 | June 29, 2025 | |
| NCT05678257 | Active, not recruiting | Phase 2 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | April 18, 2023 | March 2025 |
| NCT03173001 | Active, not recruiting | Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis | January 1, 2015 | December 31, 2025 | |
| NCT03388190 | Active, not recruiting | Phase 2 | METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin | May 29, 2018 | June 30, 2025 |
| NCT04169347 | Active, not recruiting | Phase 2 | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | December 2, 2019 | January 2025 |
| NCT03563157 | Active, not recruiting | Phase 1/Phase 2 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | May 25, 2018 | December 30, 2022 |
| NCT03133273 | Active, not recruiting | N/A | Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM) | July 24, 2017 | July 24, 2024 |
| NCT03657641 | Active, not recruiting | Phase 1/Phase 2 | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | June 21, 2019 | June 21, 2025 |
| NCT03800602 | Active, not recruiting | Phase 2 | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | January 15, 2019 | January 31, 2025 |
| NCT05243862 | Active, not recruiting | Phase 2 | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | June 2, 2022 | June 2, 2026 |
| NCT02286492 | Approved for marketing | Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer | |||
| NCT01909830 | Completed | Phase 2 | Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients | July 2012 | March 2014 |
| NCT01932489 | Completed | N/A | The Jules Bordet Institute Molecular Profiling Program Feasibility Trial | December 2013 | October 2014 |
| NCT01982227 | Completed | Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin. | March 2013 | December 2014 | |
| NCT05513183 | Completed | Severe Neutropenia After HIPEC Using Mitomycin-C | May 20, 2021 | March 20, 2023 | |
| NCT02135757 | Completed | Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients | August 2014 | March 2018 | |
| NCT02139215 | Completed | Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients | April 2014 | March 2018 | |
| NCT05475041 | Completed | Perioperative Outcomes of Simultaneous Colorectal and Liver Resections | June 30, 2022 | July 22, 2022 | |
| NCT02171286 | Completed | The Oncopanel Pilot (TOP) Study | October 2014 | March 2017 | |
| NCT02179970 | Completed | Phase 1 | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | June 2015 | December 14, 2018 |
| NCT02350400 | Completed | Phase 1 | Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI). | June 2014 | February 2016 |
| NCT01163396 | Completed | Phase 2 | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer | July 2007 | April 2010 |
| NCT02390947 | Completed | Phase 3 | Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT） | January 2015 | July 2019 |
| NCT02751177 | Completed | N/A | Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer | March 25, 2016 | May 30, 2017 |
| NCT05273489 | Completed | Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases. | January 1, 2004 | October 31, 2021 | |
| NCT05261113 | Completed | CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases | January 1, 2017 | June 30, 2021 | |
| NCT03007407 | Completed | Phase 2 | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | July 31, 2017 | August 9, 2019 |
| NCT00741481 | Completed | PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome. | June 2006 | July 2010 | |
| NCT03142516 | Completed | Phase 2 | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status | October 31, 2017 | January 21, 2021 |
| NCT03144804 | Completed | Phase 2 | A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer | October 31, 2017 | September 27, 2022 |
| NCT03164655 | Completed | Phase 2 | Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network | July 25, 2018 | November 15, 2021 |
| NCT02380443 | Completed | Phase 2 | AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer | September 2016 | September 2018 |
| NCT03898102 | Completed | Phase 2 | Zinc Supplement in Regorafenib Treated mCRC Patient | March 2016 | March 2019 |
| NCT01298570 | Completed | Phase 2 | Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer | April 7, 2011 | October 2, 2020 |
| NCT01382407 | Completed | Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab | July 2011 | April 1, 2017 | |
| NCT01471353 | Completed | Phase 2 | Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer | November 2011 | May 2017 |
| NCT01483027 | Completed | N/A | Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer | January 2012 | August 31, 2020 |
| NCT06027775 | Completed | Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases | January 1, 2013 | January 1, 2023 | |
| NCT05995990 | Completed | N/A | Raman Spectroscopy for Liver Tumours Following Liver Surgery | November 25, 2020 | December 31, 2021 |
| NCT01571284 | Completed | Phase 3 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | May 30, 2012 | January 31, 2017 |
| NCT01640444 | Completed | Phase 2 | Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) | July 2012 | November 2018 |
| NCT01661270 | Completed | Phase 3 | A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy | July 2012 | July 2015 |
| NCT01670721 | Completed | Phase 3 | Colorectal Cancer Metastatic | August 2012 | June 2015 |
| NCT01721954 | Completed | Phase 3 | FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer | May 1, 2013 | February 28, 2017 |
| NCT01762293 | Completed | Phase 2 | A Study of Famitinib in Patients With Advanced Colorectal Cancer | April 2012 | October 2014 |
| NCT01882868 | Completed | Phase 2 | A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan | July 2013 | August 2015 |
| NCT01892527 | Completed | Phase 2 | Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects | March 2013 | March 2017 |
| NCT04790448 | Completed | Phase 1/Phase 2 | Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer | July 27, 2020 | December 31, 2021 |
| NCT03556956 | Completed | Phase 2/Phase 3 | Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer | July 2015 | December 2020 |
| NCT01053013 | Completed | Phase 2 | Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer | April 15, 2010 | April 16, 2016 |
| NCT03647839 | Completed | Phase 2 | Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer | September 6, 2018 | April 9, 2021 |
| NCT04721301 | Completed | Phase 1 | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | January 15, 2017 | March 15, 2023 |
| NCT04517643 | Completed | N/A | TheraSphere® For Treatment of Metastases in Liver | November 12, 2020 | December 1, 2022 |
| NCT04482608 | Completed | The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival | September 1, 2019 | June 8, 2020 | |
| NCT03733184 | Completed | Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases | March 10, 2016 | November 30, 2019 | |
| NCT03750175 | Completed | OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - | June 1, 2018 | December 31, 2022 | |
| NCT04368507 | Completed | Phase 1/Phase 2 | To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients | August 9, 2019 | December 21, 2021 |
| NCT03775850 | Completed | Phase 1 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | December 19, 2018 | October 31, 2021 |
| NCT04898842 | Completed | N/A | Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet | March 2, 2021 | November 2, 2022 |
| NCT03202758 | Completed | Phase 1/Phase 2 | Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC | August 29, 2017 | January 9, 2023 |
| NCT03213314 | Completed | N/A | HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies | September 7, 2017 | March 31, 2019 |
| NCT03251612 | Completed | Phase 2 | Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer | September 22, 2017 | March 21, 2022 |
| NCT03439462 | Completed | Phase 1/Phase 2 | Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer | July 1, 2018 | August 26, 2022 |
| NCT03531632 | Completed | Phase 1/Phase 2 | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | June 4, 2018 | February 8, 2020 |
| NCT05353582 | Not yet recruiting | Phase 2 | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | June 1, 2022 | July 1, 2025 |
| NCT05513716 | Not yet recruiting | Molecular Characterisation of Colorectal Cancer Peritoneal Metastases | February 4, 2024 | July 3, 2025 | |
| NCT03503071 | Not yet recruiting | Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy | October 1, 2018 | December 31, 2025 | |
| NCT06456515 | Not yet recruiting | N/A | Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC | June 2024 | March 2026 |
| NCT06283303 | Not yet recruiting | Phase 1 | A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | April 2, 2024 | November 30, 2025 |
| NCT06283134 | Not yet recruiting | Phase 1 | A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | April 2, 2024 | December 1, 2027 |
| NCT05700656 | Not yet recruiting | Phase 1/Phase 2 | Galunisertib Combined With Capecitabine in Advanced CRC With PM | April 2023 | April 2025 |
| NCT05808790 | Not yet recruiting | N/A | Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy | January 1, 2024 | December 31, 2030 |
| NCT06008119 | Not yet recruiting | Phase 3 | Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | November 24, 2023 | December 24, 2026 |
| NCT04888806 | Not yet recruiting | Phase 2 | A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis | June 1, 2021 | June 30, 2025 |
| NCT05913674 | Not yet recruiting | Phase 2 | Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC) | July 2024 | January 2026 |
| NCT05727163 | Recruiting | Phase 2 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | July 29, 2022 | December 31, 2026 |
| NCT03038568 | Recruiting | Assessing How Normal Variations in CT Scanning Affects Its Interpretation | January 27, 2017 | January 27, 2025 | |
| NCT03597581 | Recruiting | Phase 1 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | June 5, 2018 | December 31, 2024 |
| NCT03803436 | Recruiting | Phase 2 | Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation | January 2, 2019 | January 2024 |
| NCT03941080 | Recruiting | Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer | September 9, 2020 | January 2024 | |
| NCT04030260 | Recruiting | Phase 2 | Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer | July 19, 2019 | July 19, 2023 |
| NCT04081168 | Recruiting | N/A | COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation | December 15, 2020 | January 15, 2025 |
| NCT04245865 | Recruiting | Phase 2 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | June 26, 2020 | October 2024 |
| NCT04262687 | Recruiting | Phase 2 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | April 6, 2021 | September 30, 2024 |
| NCT04550897 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients | August 31, 2020 | December 31, 2023 |
| NCT04564898 | Recruiting | Phase 1/Phase 2 | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. | January 25, 2022 | March 2025 |
| NCT04595266 | Recruiting | Phase 2 | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | June 29, 2021 | January 2025 |
| NCT04730544 | Recruiting | Phase 2 | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | April 13, 2021 | April 2028 |
| NCT04854213 | Recruiting | N/A | PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) | October 6, 2021 | March 2025 |
| NCT04874207 | Recruiting | Phase 4 | Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib | October 22, 2021 | May 2025 |
| NCT04999306 | Recruiting | N/A | Feasibility of 2 Interventions to Reduce Fatigue in Patients With Chemotherapy for Metastatic Colorectal Cancer | May 17, 2023 | September 2025 |
| NCT05057052 | Recruiting | Phase 2 | Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis | September 26, 2021 | September 25, 2024 |
| NCT05068531 | Recruiting | Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients | September 1, 2022 | October 2026 | |
| NCT05092880 | Recruiting | Phase 2 | Radioembolization in Elderly/ Fragile Patients With mCRC | June 1, 2022 | October 2028 |
| NCT05129787 | Recruiting | N/A | Ablation vs Resection of Colorectal Cancer Liver Metastases | December 16, 2021 | December 2025 |
| NCT05160727 | Recruiting | Phase 2 | Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer | October 1, 2021 | October 2024 |
| NCT05200442 | Recruiting | Phase 1/Phase 2 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | August 22, 2022 | August 1, 2025 |
| NCT05248581 | Recruiting | Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases | August 16, 2019 | August 1, 2027 | |
| NCT05289076 | Recruiting | Phase 1/Phase 2 | Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model | May 17, 2022 | March 14, 2025 |
| NCT05480306 | Recruiting | Phase 2 | Phase 2 Study of DKN-01 in Colorectal Cancer | August 30, 2022 | October 31, 2025 |
| NCT05501353 | Recruiting | Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods | July 22, 2022 | September 1, 2027 | |
| NCT05589597 | Recruiting | Phase 1/Phase 2 | EO4010 in Previously Treated Metastatic Colorectal Carcinoma | June 1, 2023 | February 2026 |
| NCT05611034 | Recruiting | Phase 1 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | February 6, 2023 | January 1, 2032 |
| NCT05625932 | Recruiting | Phase 3 | TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer | March 2, 2023 | March 2025 |
| NCT05665322 | Recruiting | N/A | Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver Metastases | January 31, 2023 | July 2024 |
| NCT05674526 | Recruiting | Phase 1 | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | May 21, 2024 | June 1, 2026 |
| NCT05736731 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | April 28, 2023 | December 2028 |
| NCT05759728 | Recruiting | Phase 1/Phase 2 | A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | October 24, 2023 | December 2027 |
| NCT06018714 | Recruiting | Phase 2 | Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study | May 1, 2023 | August 1, 2026 |
| NCT06282445 | Recruiting | Phase 2 | Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | March 1, 2024 | March 31, 2026 |
| NCT06300463 | Recruiting | Phase 2 | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | March 26, 2024 | March 2027 |
| NCT06332079 | Recruiting | Phase 2 | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | March 13, 2024 | February 2027 |
| NCT06353854 | Recruiting | Prospective Cohort Study of Immunotherapy Resistance in Metastatic Colorectal Cancer Patients With MSI | February 12, 2024 | February 12, 2030 | |
| NCT06379399 | Recruiting | Phase 1/Phase 2 | Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC | April 2024 | December 2025 |
| NCT06414304 | Recruiting | Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy | June 1, 2022 | July 2026 | |
| NCT06440902 | Recruiting | Phase 2 | Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA | December 28, 2023 | September 1, 2028 |
| NCT06447727 | Recruiting | Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM | May 20, 2024 | November 30, 2025 | |
| NCT06449989 | Recruiting | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer | April 1, 2024 | April 2025 | |
| NCT04108481 | Suspended | Phase 1/Phase 2 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer | October 5, 2020 | December 31, 2025 |
| NCT05584137 | Suspended | Phase 2 | Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC | June 15, 2023 | April 30, 2026 |
| NCT01668680 | Terminated | Phase 2 | Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma | September 2012 | December 2014 |
| NCT04607668 | Terminated | Phase 3 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): | October 16, 2020 | March 31, 2023 |
| NCT01508000 | Terminated | Phase 2 | Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | June 2013 | September 2016 |
| NCT01522612 | Terminated | Phase 2 | Colorectal Cancer (CRC) Cetuximab Elderly Frail | April 2013 | January 2015 |
| NCT01540344 | Terminated | Phase 2 | Combined Anticancer Treatment of Advanced Colon Cancer | October 2010 | October 2017 |
| NCT03549338 | Terminated | Phase 2 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | November 29, 2018 | March 9, 2019 |
| NCT01955629 | Terminated | Phase 1/Phase 2 | Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient | December 2013 | March 2015 |
| NCT03149679 | Terminated | Phase 2 | The p53 Colorectal Cancer Trial | May 9, 2017 | August 7, 2020 |
| NCT02316496 | Terminated | Phase 2 | Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study | September 23, 2015 | January 2017 |
| NCT01317433 | Terminated | N/A | Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer | December 29, 2010 | October 10, 2016 |
| NCT04543019 | Unknown status | Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer | December 2020 | September 2022 | |
| NCT02149784 | Unknown status | Phase 3 | Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients | September 2015 | July 2019 |
| NCT04684095 | Unknown status | N/A | The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer | May 26, 2021 | June 15, 2024 |
| NCT03697044 | Unknown status | Irinotecan Drug-eluting Bead Liver Embolisation Registry | January 2019 | January 2024 | |
| NCT01959061 | Unknown status | Phase 4 | Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases | September 2013 | December 2017 |
| NCT03488953 | Unknown status | N/A | Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases | April 10, 2018 | December 15, 2023 |
| NCT03705442 | Unknown status | Phase 2 | Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer | February 9, 2018 | February 9, 2020 |
| NCT00442637 | Unknown status | Phase 3 | Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | January 2007 | December 2013 |
| NCT02959151 | Unknown status | Phase 1/Phase 2 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | July 2016 | July 2018 |
| NCT04031872 | Unknown status | Phase 1/Phase 2 | LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) | February 2020 | July 2021 |
| NCT02948985 | Unknown status | Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC | January 2017 | December 2019 | |
| NCT04148378 | Unknown status | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | March 2, 2020 | July 2023 | |
| NCT03923036 | Unknown status | Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer | April 2019 | June 2019 | |
| NCT03792269 | Unknown status | Phase 2 | Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC | January 1, 2016 | December 2020 |
| NCT01249638 | Unknown status | Phase 3 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | December 2010 | December 2016 |
| NCT03751176 | Unknown status | Phase 2 | Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal | November 8, 2018 | November 30, 2022 |
| NCT01943786 | Unknown status | RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab | April 2013 | December 2015 | |
| NCT04525807 | Unknown status | Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory | September 1, 2020 | September 1, 2022 | |
| NCT03193710 | Unknown status | The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved | September 1, 2017 | October 2023 | |
| NCT03167268 | Unknown status | Phase 2 | Panitumumab Skin Toxicity Prevention Trial | August 3, 2016 | November 30, 2021 |
| NCT01315990 | Unknown status | Phase 4 | FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema | January 2011 | March 2018 |
| NCT03717038 | Withdrawn | Phase 3 | Sym004 Versus TAS-102 in Patients With mCRC | February 2019 | December 2025 |
| NCT01646554 | Withdrawn | Phase 2/Phase 3 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases | December 2012 | December 2016 |
| NCT04751955 | Withdrawn | Phase 1/Phase 2 | A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP) | January 1, 2022 | August 31, 2024 |
| NCT05062720 | Withdrawn | Phase 2 | Local Consolidative Therapy in Colorectal Cancer | July 29, 2021 | October 31, 2025 |
| NCT02085005 | Withdrawn | Phase 2 | Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer | March 2014 | August 2016 |
| NCT04799431 | Withdrawn | Phase 1 | Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | May 3, 2023 | May 3, 2023 |
| NCT03470350 | Withdrawn | Phase 1/Phase 2 | Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer | August 24, 2018 | June 1, 2020 |
| NCT03982121 | Withdrawn | Phase 1 | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy | June 4, 2019 | February 12, 2020 |